ArticleAddictive disorders & their treatment2017
Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection.
Article in Addictive disorders & their treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 34 citations in OpenAlex.
- Barriers to Hepatitis C Treatment and Interest in Telemedicine-Based Care Among Clients of a Syringe Access Program.Open forum infectious diseases · 2024Article
- Engaging people who use drugs in clinical research: integrating facilitated telemedicine for HCV into substance use treatment.Research involvement and engagement · 2023Article
- Review
- Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C.Journal of managed care & specialty pharmacy · 2021Article
- Hepatitis C Virus Infection in Persons Who Inject Drugs in the Middle East and North Africa: Intervention Strategies.Viruses · 2021Review
- Mobile Peer-Support for Opioid Use Disorders: Refinement of an Innovative Machine Learning Tool.Journal of psychiatry and brain science · 2020Article
- Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs.Addiction (Abingdon, England) · 2019Article
- The Current and Future Use of Telemedicine in Infectious Diseases Practice.Current infectious disease reports · 2019Review
- HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study.BMC infectious diseases · 2019Article
- Article
- Update on global epidemiology of viral hepatitis and preventive strategies.World journal of clinical cases · 2018Review
- Ledipasvir and Sofosbuvir in the Treatment of Early Hepatitis C Virus Infection in HIV-Infected Men.Open forum infectious diseases · 2018Article
- Strategies for the elimination of hepatitis C virus infection as a public health threat in the United States.Current hepatology reports · 2018Article
- The role of prevention strategies in achieving HCV elimination in Canada: what are the remaining challenges?Canadian liver journal · 2018Review
- Toward Optimal Control of Hepatitis C Virus Infection in Persons With Substance Use Disorders.Annals of internal medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Direct-acting antivirals for hepatitis C virus infection may revolutionize treatment among persons with substance use disorders. Despite persons with substance use disorders having the highest hepatitis C virus prevalence and incidence, the vast majority have not engaged into care for the infection. Previously, interferon-based treatments, with substantial side effects and the propensity to exacerbate mental health conditions, were major disincentives to pursuit of care for the infection. Direct-acting antivirals with viral eradication rates of >90%, significantly improved side effect profiles, and shorter treatment duration are dramatic improvements over prior treatment regimens that should promote widespread hepatitis C virus care among persons with substance use disorders. The major unmet need is strategies to promote persons with substance use disorders engagement into care for hepatitis C virus. Although physical integration of treatment for substance use and co-occurring conditions has been widely advocated, it has been difficult to achieve. Telemedicine offers an opportunity for virtual integration of behavioral and medical treatments that could be supplemented by conventional interventions such as hepatitis C virus education, case management, and peer navigation. Furthermore, harm reduction and strategies to reduce viral transmission are important to cease reinfection among persons with substance use disorders. Widespread prescription of therapy for hepatitis C virus infection to substance users will be required to achieve the ultimate goal of global virus elimination. Combinations of medical and behavioral interventions should be used to promote persons with substance use disorders engagement into and adherence with direct-acting antiviral-based treatment approaches. Ultimately, either physical or virtual colocation of hepatitis C virus and substance use treatment has the potential to improve adherence and consequently treatment efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.